AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026350451
Cite this article
2
Download
9
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Incremental value of needle-trajectory radiomics using publicly available three-dimensional transrectal ultrasound data for detecting core-level clinically significant prostate cancer

Yongzhe Zheng1† ,  Lixin Wang1† ,  Guangming Jin1*
Show Less
1 Department of Ultrasound Medicine, Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, Jilin , China
†These authors contributed equally to this work.
Received: 27 August 2026 | Revised: 1 October 2026 | Accepted: 22 October 2026 | Published online: 16 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Transrectal ultrasound (TRUS) radiomics has shown potential for prostate cancer detection, but previous studies have primarily extracted features from lesions or broad anatomical regions. The diagnostic value of ultrasound features surrounding individual biopsy needle trajectories remains unclear.

Objective: To determine whether radiomic features extracted from regions surrounding tracked needle trajectories in three-dimensional (3D) TRUS improve core-level discrimination of clinically significant prostate cancer (csPCa) beyond clinical and anatomical location information.

Methods: We retrospectively analyzed the public Prostate-MRI-US-Biopsy cohort, including 1,129 patients with 17,559 cores. csPCa was defined as a Gleason score of ≥ 7. Cylindrical regions (5-mm radius, with 3-mm and 7-mm sensitivity analyses) were centered on trajectory paths, and 93 PyRadiomics features were extracted. Three L1-penalized logistic regression models (clinical/location baseline, trajectory-radiomics, and combined) were evaluated using nested patient-grouped cross-validation and patient-cluster bootstrap resampling.

Results: After quality control, 16,259 cores (1,561 csPCa) were analyzed. No radiomic feature was selected in any outer fold of the combined model. Areas under the receiver operating characteristic curve (AUCs) for baseline, trajectory-radiomics, and combined models were 0.812, 0.543, and 0.819, respectively. The combined-minus-baseline AUC difference was 0.0065 (p < 0.001), attributable to fold-specific regularization rather than radiomic information, and the combined model had a higher (worse) Brier score than the baseline model (0.196 vs. 0.189).

Conclusion: Tracked coordinates enabled region construction, but conventional trajectory radiomics provided no attributable or clinically meaningful incremental value over clinical/location data. Independent validation is required before clinical application.

Keywords
Prostate cancer
Transrectal ultrasound
Radiomics
Biopsy
Needle
Funding
This research was funded by the Natural Science Foundation of Jilin Province (grant no. YDZJ202201ZYTS204).
Conflict of interest
The authors declare that they have no competing interests.
References
  1. Natarajan S, Marks LS, Margolis DJA, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011;29(3):334-342. doi: 10.1016/j.urolonc.2011.02.014
  2. Baumann M, Mozer P, Daanen V, Troccaz J. Prostate biopsy tracking with deformation estimation. Med Image Anal. 2012;16(3):562-576. doi: 10.1016/j.media.2011.01.008
  3. Sonn GA, Natarajan S, Margolis DJA, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013;189(1):86-92. doi: 10.1016/j.juro.2012.08.095
  4. Wildeboer RR, Mannaerts CK, van Sloun RJG, et al. Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics. Eur Radiol. 2020;30(2):806-815. doi: 10.1007/s00330-019-06436-w
  5. Chen P, Turco S, Wang Y, et al. Can 3D multiparametric ultrasound imaging predict prostate biopsy outcome? Ultrasound Med Biol. 2024;50(8):1194-1202. doi: 10.1016/j.ultrasmedbio.2024.04.007
  6. Sun Y, Fang J, Shi Y, et al. Machine learning based on radiomics features combing B-mode transrectal ultrasound and contrast-enhanced ultrasound to improve peripheral zone prostate cancer detection. Abdom Radiol (NY). 2024;49(1):141-150. doi: 10.1007/s00261-023-04050-5
  7. Wilson PFR, Gilany M, Jamzad A, et al. Self-supervised learning with limited labeled data for prostate cancer detection in high-frequency ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control. 2023;70(9):1073-1083. doi: 10.1109/TUFFC.2023.3297840
  8. Gilany M, Wilson P, Perera-Ortega A, et al. TRUSformer: improving prostate cancer detection from micro-ultrasound using attention and self-supervision. Int J Comput Assist Radiol Surg. 2023;18(7):1193-1200. doi: 10.1007/s11548-023-02949-4
  9. Huang Y, Qian H, Zheng Y, Song H, Liu X. A radiomics model based on transrectal ultrasound for predicting prostate cancer. Med Ultrason. 2024;26(2):138-146. doi: 10.11152/mu-4329
  10. Natarajan S, Priester A, Margolis D, Huang J, Marks L. Prostate MRI and Ultrasound With Pathology and Coordinates of Tracked Biopsy (Prostate-MRI-US-Biopsy) (version 2) [data set]. The Cancer Imaging Archive. 2020. doi: 10.7937/TCIA.2020.A61IOC1A
  11. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104-e107. doi: 10.1158/0008-5472.CAN-17-0339
  12. Zwanenburg A, Vallières M, Abdalah MA, et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328-338. doi: 10.1148/radiol.2020191145
  13. Kocak B, Baessler B, Bakas S, et al. CheckList for EvaluAtion of Radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII. Insights Imaging. 2023;14:75. doi: 10.1186/s13244-023-01415-8
  14. Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):230. doi: 10.1186/s12916-019-1466-7
  15. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-574. doi: 10.1177/0272989X06295361
  16. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. doi: 10.1136/bmj-2023-078378
  17. Li H, Yu WL, Wu ML. Jing zichang jianqiebo tanxingchengxiang dui cunzai xia niaolu zhengzhuang de qianliexian bingbian liang-exing de jianbie zhenduan jiazhi ji qi yingxiang yinsu fenxi [Value of transrectal shear-wave elastography in differential diagnosis of benign and malignant prostate lesions with lower urinary tract symptoms and factors related to severity of such symptoms]. Chin J Med Ultrasound (Electronic Edition). 2023;20(11):1193-1198. [In Chinese]. doi: 10.3877/cma.j.issn.2096-1537.2023.11.014
  18. Zhang Q, Zhou C, Chen Y, Luo Y. Artificial intelligence for prostate cancer detection and risk stratification using transrectal ultrasound: a narrative review. Gland Surg. 2026;15(2):52. doi: 10.21037/gs-2025-aw-504
  19. Lou W, Chen P, Wu C, et al. Prostate cancer classification using 3D deep learning and ultrasound video clips: a multicenter study. Front Oncol. 2025;15:1582035. doi: 10.3389/fonc.2025.1582035
  20. Liu X, Zhang ZX, Zheng B, Xu M, Cao XY, Huang HM. A retrospective study on predicting clinically significant prostate cancer via a bi-parametric ultrasound-based deep learning radiomics model. Front Oncol. 2025;15:1538854. doi: 10.3389/fonc.2025.1538854
  21. Sun YK, Zhou BY, Miao Y, et al. Three-dimensional convolutional neural network model to identify clinically significant prostate cancer in transrectal ultrasound videos: a prospective, multi-institutional, diagnostic study. EClinicalMedicine. 2023;60:102027. doi: 10.1016/j.eclinm.2023.102027
  22. Qi XY, Wang K, Feng BJ, et al. Comparison of machine learning models based on multi-parametric magnetic resonance imaging and ultrasound videos for the prediction of prostate cancer. Front Oncol. 2023;13:1157949. doi: 10.3389/fonc.2023.1157949
  23. Miao KH, Miao JH, Finkelstein M, Chatterjee A, Oto A. Next-generation advances in prostate cancer imaging and artificial intelligence applications. J Imaging. 2025;11(11):390. doi: 10.3390/jimaging11110390
  24. Pepe P, Pepe L, Fiorentino V, Curduman M, Fraggetta F. Multiparametric MRI targeted prostate biopsy: when omit systematic biopsy? Arch Ital Urol Androl. 2024;96(4):12992. doi: 10.4081/aiua.2024.12992
  25. Drost FJH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):CD012663. doi: 10.1002/14651858.CD012663.pub2
  26. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi: 10.1056/NEJMoa1801993
  27. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749-762. doi: 10.1038/nrclinonc.2017.141
  28. Park JE, Kim D, Kim HS, et al. Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPOD statement. Eur Radiol. 2020;30(1):523-536. doi: 10.1007/s00330-019-06360-z
  29. Kocak B, Durmaz ES, Erdim C, Ates E, Kaya OK, Kilickesmez O. Radiomics of renal masses: systematic review of reproducibility and validation strategies. AJR Am J Roentgenol. 2020;214(1):129-136. doi: 10.2214/AJR.19.21709
  30. Park JE, Kim HS, Kim D, et al. A systematic review reporting quality of radiomics research in neuro-oncology: toward clinical utility and quality improvement using high-dimensional imaging features. BMC Cancer. 2020;20(1):29. doi: 10.1186/s12885-019-6504-5
  31. Kocak B, Akinci D'Antonoli T, Mercaldo N, et al. METhodological RadiomICs Score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII. Insights Imaging. 2024;15(1):8. doi: 10.1186/s13244-023-01572-w
  32. Cuocolo R, Cipullo MB, Stanzione A, et al. Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis. Eur Radiol. 2020;30(12):6877-6887. doi: 10.1007/s00330-020-07027-w
  33. Stanzione A, Gambardella M, Cuocolo R, Ponsiglione A, Romeo V, Imbriaco M. Prostate MRI radiomics: a systematic review and radiomic quality score assessment. Eur J Radiol. 2020;129:109095. doi: 10.1016/j.ejrad.2020.109095
  34. Woźnicki P, Westhoff N, Huber T, et al. Multiparametric MRI for prostate cancer characterization: combined use of radiomics model with PI-RADS and clinical parameters. Cancers (Basel). 2020;12(7):1767. doi: 10.3390/cancers12071767
  35. Brembilla G, Giganti F, Sidhu H, et al. Diagnostic accuracy of abbreviated bi-parametric MRI (a-bpMRI) for prostate cancer detection and screening: a multi-reader study. Diagnostics (Basel). 2022;12(2):231. doi: 10.3390/diagnostics12020231
  36. Castillo TJM, Starmans MPA, Arif M, et al. A multi-center, multi-vendor study to evaluate the generalizability of a radiomics model for classifying prostate cancer: high grade vs low grade. Diagnostics (Basel). 2021;11(2):369. doi: 10.3390/diagnostics11020369
  37. Smith CP, Czarniecki M, Mehralivand S, et al. Radiomics and radiogenomics of prostate cancer. Abdom Radiol (NY). 2019;44(6):2021-2029. doi: 10.1007/s00261-018-1660-7
  38. Chaddad A, Kucharczyk MJ, Niazi T. Multimodal radiomic features for the predicting Gleason score of prostate cancer. Cancers (Basel). 2018;10(8):249. doi: 10.3390/cancers10080249
  39. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100-109. doi: 10.1016/S1470-2045(18)30569-2
  40. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382(10):917-928. doi: 10.1056/NEJMoa1910038
  41. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033
  42. Padhani AR, Barentsz J, Villeirs G, et al. PI-RADS Steering Committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology. 2019;292(2):464-474. doi: 10.1148/radiol.2019182946
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing